JP2000505789A - 注射及び輸液用として血管内に使用する改良された濃縮溶液 - Google Patents
注射及び輸液用として血管内に使用する改良された濃縮溶液Info
- Publication number
- JP2000505789A JP2000505789A JP9526441A JP52644197A JP2000505789A JP 2000505789 A JP2000505789 A JP 2000505789A JP 9526441 A JP9526441 A JP 9526441A JP 52644197 A JP52644197 A JP 52644197A JP 2000505789 A JP2000505789 A JP 2000505789A
- Authority
- JP
- Japan
- Prior art keywords
- solution
- infusion
- injection
- additive
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000002347 injection Methods 0.000 title claims abstract description 58
- 239000007924 injection Substances 0.000 title claims abstract description 58
- 239000000243 solution Substances 0.000 title claims description 117
- 238000001802 infusion Methods 0.000 title claims description 55
- 239000000654 additive Substances 0.000 claims abstract description 68
- 230000001154 acute effect Effects 0.000 claims abstract description 34
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims abstract description 31
- 239000003978 infusion fluid Substances 0.000 claims abstract description 16
- 239000002872 contrast media Substances 0.000 claims description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- 230000000996 additive effect Effects 0.000 claims description 39
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 38
- 239000000126 substance Substances 0.000 claims description 38
- 230000000694 effects Effects 0.000 claims description 23
- 239000013543 active substance Substances 0.000 claims description 22
- 239000011734 sodium Substances 0.000 claims description 20
- 239000011780 sodium chloride Substances 0.000 claims description 19
- 235000001014 amino acid Nutrition 0.000 claims description 18
- 229940024606 amino acid Drugs 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 17
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 14
- 239000003146 anticoagulant agent Substances 0.000 claims description 14
- 229960002897 heparin Drugs 0.000 claims description 14
- 229920000669 heparin Polymers 0.000 claims description 14
- 229940127219 anticoagulant drug Drugs 0.000 claims description 13
- 239000000872 buffer Substances 0.000 claims description 13
- 239000003792 electrolyte Substances 0.000 claims description 13
- 239000007983 Tris buffer Substances 0.000 claims description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 11
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 10
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 10
- 239000004472 Lysine Substances 0.000 claims description 9
- 235000018977 lysine Nutrition 0.000 claims description 9
- 229960003646 lysine Drugs 0.000 claims description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 8
- 230000024203 complement activation Effects 0.000 claims description 8
- -1 MgCl 2 Chemical compound 0.000 claims description 7
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 6
- 229960002684 aminocaproic acid Drugs 0.000 claims description 6
- 239000004202 carbamide Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 239000001632 sodium acetate Substances 0.000 claims description 6
- 235000017281 sodium acetate Nutrition 0.000 claims description 6
- NCAJWYASAWUEBY-UHFFFAOYSA-N 3-[20-(2-carboxyethyl)-9,14-diethyl-5,10,15,19-tetramethyl-21,22,23,24-tetraazapentacyclo[16.2.1.1^{3,6}.1^{8,11}.1^{13,16}]tetracosa-1(21),2,4,6(24),7,9,11,13,15,17,19-undecaen-4-yl]propanoic acid Chemical compound N1C2=C(C)C(CC)=C1C=C(N1)C(C)=C(CC)C1=CC(C(C)=C1CCC(O)=O)=NC1=CC(C(CCC(O)=O)=C1C)=NC1=C2 NCAJWYASAWUEBY-UHFFFAOYSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 108010024636 Glutathione Proteins 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 229960003180 glutathione Drugs 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 230000007935 neutral effect Effects 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 4
- 108010039918 Polylysine Proteins 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 239000008139 complexing agent Substances 0.000 claims description 4
- 239000000539 dimer Substances 0.000 claims description 4
- 229930182830 galactose Natural products 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 229960003194 meglumine Drugs 0.000 claims description 4
- 229920000656 polylysine Polymers 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 150000008163 sugars Chemical class 0.000 claims description 4
- VVLAIYIMMFWRFW-UHFFFAOYSA-N 2-hydroxyethylazanium;acetate Chemical compound CC(O)=O.NCCO VVLAIYIMMFWRFW-UHFFFAOYSA-N 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 3
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 229960003121 arginine Drugs 0.000 claims description 3
- 235000009697 arginine Nutrition 0.000 claims description 3
- 235000009582 asparagine Nutrition 0.000 claims description 3
- 229960001230 asparagine Drugs 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 3
- 229960001076 chlorpromazine Drugs 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 229960002433 cysteine Drugs 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 3
- 235000005772 leucine Nutrition 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- 235000008729 phenylalanine Nutrition 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims description 3
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 claims description 3
- 229960005314 suramin Drugs 0.000 claims description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 229960003104 ornithine Drugs 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 claims 1
- 239000007979 citrate buffer Substances 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 17
- 239000012153 distilled water Substances 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 206010020751 Hypersensitivity Diseases 0.000 description 12
- XUHXFSYUBXNTHU-UHFFFAOYSA-N Iotrolan Chemical compound IC=1C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C=1N(C)C(=O)CC(=O)N(C)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I XUHXFSYUBXNTHU-UHFFFAOYSA-N 0.000 description 9
- 229960003182 iotrolan Drugs 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000002583 angiography Methods 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010020852 Hypertonia Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 230000004154 complement system Effects 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 2
- 229960004359 iodixanol Drugs 0.000 description 2
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 2
- 229960002603 iopromide Drugs 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010030111 Oedema mucosal Diseases 0.000 description 1
- 229940079172 Osmotic diuretic Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 229940021013 electrolyte solution Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
- 229960001025 iohexol Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000002337 osmotic diuretic agent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0452—Solutions, e.g. for injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 急性又は遅発性過敏反応を、回避又は減少させるための、1〜2000mmol/l の濃度において、濃縮した注射及び輸液用の溶液に加える添加剤としての、生理 的和合性の、会合していない電解質又は緩衝剤の使用。 2. 0.5mg/mlを超える濃度において錯体形成剤の塩を使用することを特徴とす る請求項1の使用。 3. 無機塩を使用することを特徴とする請求項1の使用。 4. NaClを、60mmol/lを超える濃度において、単量体のノニオン性造影剤 に加える添加剤として使用することを特徴とする請求項3の使用。 5. NaClを、80mmol/lを超える濃度において、二量体のノニオン性造影剤 に加える添加剤として使用することを特徴とする請求項3の使用。 6. 30mmol/lを超える濃度においてクエン酸塩緩衝剤又はトリス緩衝剤を使用 することを特徴とする請求項1の使用。 7. 急性又は遅発性過敏反応を、回避又は減少させるための、合計オスモル濃 度を、少なくとも100mmol/kg水だけ、塩化ナトリウムの場合には、少なくとも16 0mosm/kg水から400〜1500mosm/kg水まで高める作用をする濃度において、濃縮し た注射及び輸液用の溶液に添加剤として加える、オスモル濃度を高める物質の使 用。 8. 遅発性過敏反応を、回避又は減少させるための、造影剤分子の中に存在す る酸性の水素原子を置換する量を超える量において、イオン性又はノニオン性の 造影剤溶液に添加剤として加える、アミノ酸、その塩及びアミドの使用。 9. 急性又は遅発性過敏反応を、回避又は減少させるための、0.01〜100mg/ml の濃度において、濃縮した、又は粒子を含有する注射及び輸液用の溶液に加える 添加剤としての、補体活性の阻害物の使用。 10.急性又は遅発性過敏反応を、回避又は減少させるための、0.1〜50IE/mlの 濃度において、濃縮した、又は粒子を含有する注射及び輸液用の溶液に加える添 加剤としての、ヘパリン又はその他の凝固防止物の使用。 11.請求項1〜10記載の急性又は遅発性過敏反応を、回避又は減少させるた めの、濃縮した、又は粒子を含有する注射及び輸液用の溶液に加える添加剤とし ての、次の物質群: a)オスモル濃度を高める物質、 b)アミノ酸、 c)補体活性の阻害物、 d)凝固防止物質及び/又は e)尿素 の少なくとも2つの物質群の複合使用。 12.請求項1〜11のいずれか1項記載の添加剤の、造影剤溶液への使用。 13.請求項1〜11のいずれか1項記載の添加剤の、ノニオン性の二量体造影 剤溶液への使用。 14. NaCl、MgCl2、酢酸ナトリウム、塩化メグルミン、Na2CaEDTAの、請求項 1及び11記載の電解質としての使用。 15.グリシン、ロイシン、リシン、アスパラギン、アスパラギン酸、フェニル アラニン、トリプトファン及びそれらの塩、並びにアミドの、請求項8及び11 記載のアミノ酸としての使用。 16.トリス及びクエン酸ナトリウムの、請求項1及び11記載の 緩衝剤としての使用。 17.生理的和合性を有する無機塩又は有機塩、アミノ酸の塩、糖及びアルコー ルの、請求項7及び11記載によるオスモル濃度を高める物質としての使用。 18. NaCl、酢酸ナトリウム、エタノールアミン酢酸塩、グルコース、ガラク トース、リボース、プロパンジオール、グリセリン及びマンニトールの、請求項 2及び6記載のオスモル濃度を高める物質としての使用。 19.ヘパリン、ε−アミノカプロン酸、リシン、アルギニン、オルニチン、シ ステイン、ホモシステイン、ペプチド、ポリペプチド、トリプトファン−チロシ ン、グルタチオン、ポリリシン、ポリイノシン酸、スラミン、クロルプロマジン 又はメソポルフィリンの、請求項9、10及び11記載の補体活性の阻害物また は凝固防止物としての使用。 20.急性又は遅発性過敏反応を、回避又は減少させるために、1〜2000mmol/l の濃度において、生理的和合性の中性アミド、電解質又は緩衝剤からなる添加剤 を含有する輸液及び注射用の溶液。 21. 0.5mg/mlを超える濃度にある錯体形成剤の塩の含有量を特徴とする請求 項20記載の輸液及び注射用の溶液。 22.1〜2000mmol/lの濃度にある無機塩の含有量を特徴とする請求項20記載 の輸液及び注射用の溶液。 23.60 mmol/lを超える濃度において、単量体のノニオン性造影剤に添加剤と して加えるNaClの含有量を特徴とする請求項22記載の輸液及び注射用の溶 液。 24.80 mmol/lを超える濃度において、二量体のノニオン性造影剤に添加剤と して加えるNaClの含有量を特徴とする請求項22記載の輸液及び注射用の溶 液。 25.急性又は遅発性過敏反応を、回避し、又は減少させるために、合計オスモ ル濃度を、少なくとも100mmol/kg水だけ、塩化ナトリウムの場合には、少なくと も160mosm/kg水から400〜1500mosm/kg水まで高める作用をする濃度において、オ スモル濃度を高める物質よりなる添加剤を含有する輸液及び注射用の溶液。 26.急性又は遅発性過敏反応を、回避し、又は減少させるために、造影剤分子 の中に存在する酸性の水素原子を置換する量を超える量において、アミノ酸より なる添加剤を含有する輸液及び注射用の溶液。 27.急性又は遅発性過敏反応を、回避又は減少させるために、0.01〜100mg/ml の濃度において、補体活性の阻害物よりなる添加剤を含有する輸液及び注射用の 溶液。 28.急性又は遅発性過敏反応を、回避又は減少させるために、0.1〜50IE/mlに 相当する濃度において、ヘパリン又はその他の凝固防止物を含有する輸液及び注 射用の溶液。 29.請求項20〜29記載の急性又は遅発性過敏反応を、回避又は減少させる ために、次の物質群: a)オスモル濃度を高める物質、 b)アミノ酸、 c)補体活性の阻害物、 d)凝固防止物質及び/又は e)尿素 の少なくとも2つの物質群を含有する輸液及び注射用の溶液。 30.溶液が、活性物質として造影剤を含有することを特徴とする請求項20〜 29記載の輸液及び注射用の溶液。 31.溶液が、活性物質としてノニオン性造影剤を含有することを特徴とする請 求項30記載の輸液及び注射用の溶液。 32.溶液が、活性物質としてノニオン性の二量体造影剤を含有することを特徴 とする請求項30記載の輸液及び注射用の溶液。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19604095.7 | 1996-01-25 | ||
DE19604095 | 1996-01-25 | ||
PCT/DE1997/000170 WO1997026862A2 (de) | 1996-01-25 | 1997-01-27 | Verbesserte konzentrierte injektions- und infusionslösungen für die intravasale anwendung |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000505789A true JP2000505789A (ja) | 2000-05-16 |
JP2000505789A5 JP2000505789A5 (ja) | 2004-11-11 |
Family
ID=7784538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9526441A Ceased JP2000505789A (ja) | 1996-01-25 | 1997-01-27 | 注射及び輸液用として血管内に使用する改良された濃縮溶液 |
Country Status (21)
Country | Link |
---|---|
US (1) | US6638913B1 (ja) |
EP (1) | EP0876140B1 (ja) |
JP (1) | JP2000505789A (ja) |
KR (1) | KR100505772B1 (ja) |
CN (1) | CN1209751A (ja) |
AT (1) | ATE251893T1 (ja) |
AU (1) | AU2150497A (ja) |
BG (1) | BG62913B1 (ja) |
BR (1) | BR9707081A (ja) |
CA (1) | CA2244209C (ja) |
CZ (1) | CZ234898A3 (ja) |
DE (2) | DE19703816A1 (ja) |
DK (1) | DK0876140T3 (ja) |
ES (1) | ES2208884T3 (ja) |
HU (1) | HUP9901355A3 (ja) |
IL (1) | IL124676A0 (ja) |
NO (1) | NO983438L (ja) |
PL (1) | PL328199A1 (ja) |
PT (1) | PT876140E (ja) |
SK (1) | SK101398A3 (ja) |
WO (1) | WO1997026862A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021521226A (ja) * | 2018-04-16 | 2021-08-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 高濃度タンパク質製剤の粘度低下 |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
ATE286743T1 (de) * | 1997-10-31 | 2005-01-15 | Us Army | Verwendung von inhibitoren der komplementaktivierung zur herstellung eines medikaments zur inhibierung von nebenwirkungen von pharmazeutischen zusammensetzungen, die amphiphile träger oder wirkstoffträger moleküle enthalten |
AU751772C (en) | 1998-04-01 | 2006-09-07 | Correvio International Sàrl | Aminocyclohexyl ether compounds and uses thereof |
US7057053B2 (en) | 2000-10-06 | 2006-06-06 | Cardiome Pharma Corp. | Ion channel modulating compounds and uses thereof |
US7524879B2 (en) | 2000-10-06 | 2009-04-28 | Cardiome Pharma Corp. | Ion channel modulating compounds and uses thereof |
DK1324776T4 (en) | 2000-10-12 | 2018-05-28 | Genentech Inc | CONCENTRATED PROTEIN FORMULATIONS WITH REDUCED VISCOSITY |
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
DE10115740A1 (de) | 2001-03-26 | 2002-10-02 | Ulrich Speck | Zubereitung für die Restenoseprophylaxe |
US20020169112A1 (en) * | 2001-05-08 | 2002-11-14 | Luc Montagnier | Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections |
DE10244847A1 (de) | 2002-09-20 | 2004-04-01 | Ulrich Prof. Dr. Speck | Medizinische Vorrichtung zur Arzneimittelabgabe |
PL227937B1 (pl) | 2003-05-02 | 2018-01-31 | Cardiome Pharma Corp | Sposób wytwarzania związku typu eteru aminocykloheksylowego, związek typu eteru aminocykloheksylowego, jego kompozycja, sposób modulowania aktywności kanałów jonowych, oraz zastosowanie związku typu eteru aminocykloheksylowego do wytwarzania leku |
US7345087B2 (en) | 2003-10-31 | 2008-03-18 | Cardiome Pharma Corp. | Aminocyclohexyl ether compounds and uses thereof |
US8058304B2 (en) | 2004-04-01 | 2011-11-15 | Cardiome Pharma Corp. | Merged ion channel modulating compounds and uses thereof |
US7977373B2 (en) | 2004-04-01 | 2011-07-12 | Cardiome Pharma Corp. | Prodrugs of ion channel modulating compounds and uses thereof |
CA2586918C (en) | 2004-11-08 | 2021-01-19 | Cardiome Pharma Corp. | Use of ion channel modulating compounds for treating acute atrial fibrillation in a human |
US20060270708A1 (en) * | 2005-05-25 | 2006-11-30 | Navinta Llc | Novel process for preparation of isotonic aqueous injection of ropivacaine |
EP1897535A1 (en) * | 2006-08-30 | 2008-03-12 | Dirinco AG | Substitution fluid for haemofiltration |
US20090239894A1 (en) * | 2008-03-20 | 2009-09-24 | Bjorn Schurad | Stabilized aqueous solutions of ergoline compounds |
KR20110128333A (ko) | 2009-03-06 | 2011-11-29 | 제넨테크, 인크. | 항체 제제 |
US9427186B2 (en) * | 2009-12-04 | 2016-08-30 | Endomagnetics Ltd. | Magnetic probe apparatus |
US10634741B2 (en) * | 2009-12-04 | 2020-04-28 | Endomagnetics Ltd. | Magnetic probe apparatus |
LT2542257T (lt) | 2010-03-01 | 2017-11-27 | Bayer Healthcare Llc | Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi) |
CN102319258B (zh) * | 2011-08-04 | 2012-10-31 | 山西诺成制药有限公司 | 一种5%葡萄糖置换液及其制备方法 |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
CN105283202B (zh) | 2013-03-11 | 2019-04-23 | 安都磁学有限公司 | 用于***检测的低渗溶液 |
US9234877B2 (en) | 2013-03-13 | 2016-01-12 | Endomagnetics Ltd. | Magnetic detector |
US9239314B2 (en) | 2013-03-13 | 2016-01-19 | Endomagnetics Ltd. | Magnetic detector |
KR20150134346A (ko) * | 2013-03-27 | 2015-12-01 | 지이 헬스케어 에이에스 | 진단 조성물을 제조하기 위한 방법 및 시약 |
ES2833377T3 (es) | 2015-06-04 | 2021-06-15 | Endomagnetics Ltd | Materiales marcadores y formas de localizar un marcador magnético |
CN110327292A (zh) * | 2019-08-11 | 2019-10-15 | 天津乾丰瑞科技有限公司 | 一种盐酸法舒地尔注射制剂及其制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE754523A (fr) * | 1969-08-06 | 1971-02-08 | Beecham Group Ltd | Vaccins |
BE877443A (fr) * | 1978-07-04 | 1980-01-03 | Nyegaard & Co As | Procede de preparation d'unesolution tamponnee d'une substance de contraste pour rayons x |
EP0077354A4 (en) * | 1981-04-27 | 1983-09-30 | Baxter Travenol Lab | DIALYSIS SOLUTION CONTAINING GLUCOSE, AMINO ACIDS AND INSULIN. |
ATE82500T1 (de) * | 1984-06-22 | 1992-12-15 | Richard L Veech | Elektrolytloesungen und deren (in vivo) verwendung. |
IE60901B1 (en) * | 1986-08-21 | 1994-08-24 | Vestar Inc | Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics |
US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
GB8906130D0 (en) * | 1989-03-17 | 1989-05-04 | Nycomed As | Compositions |
JPH0341033A (ja) * | 1989-07-07 | 1991-02-21 | Kyowa Hakko Kogyo Co Ltd | 安定なモチリン類含有製剤 |
DE59007142D1 (de) | 1990-01-18 | 1994-10-20 | Cereria Amos Sgarbi Spa | Grablicht. |
GB9020091D0 (en) * | 1990-09-14 | 1990-10-24 | Nycomed As | Contrast media |
DE4135193C1 (ja) * | 1991-10-22 | 1993-03-11 | Schering Ag Berlin Und Bergkamen, 1000 Berlin, De | |
IT1256248B (it) * | 1992-12-24 | 1995-11-29 | Bracco Spa | Formulazioni iniettabili acquose per radiodiagnostica comprendenti miscele di composti aromatici iodurati utili come agenti opacizzanti ai raggi x |
WO1995026331A1 (es) * | 1994-03-25 | 1995-10-05 | Centro Investigacion Justesa Imagen, S.A. | Nuevos dimeros iodados no ionicos como agentes de contraste a los rayos x, metodo para su preparacion y composiciones farmaceuticas que los contienen |
DE4446694A1 (de) * | 1994-12-09 | 1996-06-13 | Schering Ag | Verwendung von Zusätzen zu Kontrastmitteln zur Verbesserung der Bildgebung |
-
1997
- 1997-01-27 PL PL97328199A patent/PL328199A1/xx unknown
- 1997-01-27 SK SK1013-98A patent/SK101398A3/sk unknown
- 1997-01-27 ES ES97914098T patent/ES2208884T3/es not_active Expired - Lifetime
- 1997-01-27 DE DE19703816A patent/DE19703816A1/de not_active Withdrawn
- 1997-01-27 AT AT97914098T patent/ATE251893T1/de not_active IP Right Cessation
- 1997-01-27 WO PCT/DE1997/000170 patent/WO1997026862A2/de not_active Application Discontinuation
- 1997-01-27 CZ CZ982348A patent/CZ234898A3/cs unknown
- 1997-01-27 CN CN97191871A patent/CN1209751A/zh active Pending
- 1997-01-27 DK DK97914098T patent/DK0876140T3/da active
- 1997-01-27 HU HU9901355A patent/HUP9901355A3/hu unknown
- 1997-01-27 KR KR10-1998-0705697A patent/KR100505772B1/ko not_active IP Right Cessation
- 1997-01-27 EP EP97914098A patent/EP0876140B1/de not_active Expired - Lifetime
- 1997-01-27 JP JP9526441A patent/JP2000505789A/ja not_active Ceased
- 1997-01-27 AU AU21504/97A patent/AU2150497A/en not_active Abandoned
- 1997-01-27 CA CA002244209A patent/CA2244209C/en not_active Expired - Fee Related
- 1997-01-27 DE DE59710863T patent/DE59710863D1/de not_active Expired - Fee Related
- 1997-01-27 IL IL12467697A patent/IL124676A0/xx unknown
- 1997-01-27 BR BR9707081A patent/BR9707081A/pt not_active IP Right Cessation
- 1997-01-27 PT PT97914098T patent/PT876140E/pt unknown
-
1998
- 1998-07-21 BG BG102644A patent/BG62913B1/bg unknown
- 1998-07-24 NO NO983438A patent/NO983438L/no not_active Application Discontinuation
-
2000
- 2000-02-14 US US09/504,108 patent/US6638913B1/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021521226A (ja) * | 2018-04-16 | 2021-08-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 高濃度タンパク質製剤の粘度低下 |
JP7465814B2 (ja) | 2018-04-16 | 2024-04-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 高濃度タンパク質製剤の粘度低下 |
Also Published As
Publication number | Publication date |
---|---|
PL328199A1 (en) | 1999-01-18 |
HUP9901355A3 (en) | 2000-06-28 |
CN1209751A (zh) | 1999-03-03 |
KR19990081979A (ko) | 1999-11-15 |
BR9707081A (pt) | 1999-05-25 |
PT876140E (pt) | 2004-02-27 |
DE19703816A1 (de) | 1997-08-07 |
WO1997026862A2 (de) | 1997-07-31 |
IL124676A0 (en) | 1998-12-06 |
AU2150497A (en) | 1997-08-20 |
NO983438D0 (no) | 1998-07-24 |
EP0876140B1 (de) | 2003-10-15 |
WO1997026862A3 (de) | 1997-10-23 |
BG62913B1 (bg) | 2000-11-30 |
KR100505772B1 (ko) | 2005-10-25 |
DK0876140T3 (da) | 2003-12-15 |
NO983438L (no) | 1998-09-18 |
HUP9901355A2 (hu) | 1999-08-30 |
SK101398A3 (en) | 1998-12-02 |
DE59710863D1 (de) | 2003-11-20 |
BG102644A (en) | 1999-06-30 |
EP0876140A2 (de) | 1998-11-11 |
CA2244209A1 (en) | 1997-07-31 |
CA2244209C (en) | 2007-10-23 |
ATE251893T1 (de) | 2003-11-15 |
ES2208884T3 (es) | 2004-06-16 |
US6638913B1 (en) | 2003-10-28 |
CZ234898A3 (cs) | 1998-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000505789A (ja) | 注射及び輸液用として血管内に使用する改良された濃縮溶液 | |
RU2311922C2 (ru) | Свободные от цинка и обедненные цинком инсулиновые композиции с повышенной стабильностью | |
KR101966484B1 (ko) | 인슐린 및 인슐린 유사체의 약동학 및 약역학과 주사 통증을 조절하기 위한 마그네슘 조성물 | |
US6548079B1 (en) | Moxifloxacin formulation containing common salt | |
JP2011500581A (ja) | 即効型注射可能インスリン組成物 | |
JP2002504908A (ja) | 安定なインスリン製剤 | |
US6150331A (en) | Human growth hormone-containing aqueous pharmaceutical composition | |
JPH0822815B2 (ja) | 高度にフツ素化された有機化合物の安定乳濁液 | |
JPH0714882B2 (ja) | 循環器系ショックに対する高浸透圧等塩素性製剤 | |
WO2007114791A1 (en) | Lactate and calcium containing pharmaceutical composition and uses thereof | |
JP2005532288A (ja) | アロステリックエフェクター化合物を含んだ安定製剤の製造と使用 | |
JPH06247872A (ja) | 高濃度tcf製剤 | |
CN107106659B (zh) | 肠胃外胰高血糖素制剂 | |
CA2416600A1 (en) | Freeze-dried preparation of n-¬o-(p-pivaloyloxybenzenesulfonylamino)benzoyl|glycine monosodium salt tetrahydrate and a process for the maufacture thereof | |
EP2106791A1 (en) | Glutamine or glutamine-containing dipeptide in a specific dosage for the treatment of inflammation | |
WO2018153506A1 (en) | Fast-acting insulin composition comprising a citric acid salt | |
AU763521B2 (en) | Improved concentrated injection and infusion solutions for intravascular use | |
JP2946015B2 (ja) | 安定な抗ウィルス点滴用注射剤 | |
WO2006096079A2 (en) | Pharmaceutical composition comprising a biosynthetic analog of human insulin, and its use in the treatment of diabetes mellitus. | |
JPS63179831A (ja) | インシュリン製剤 | |
JP2022549201A (ja) | 皮下注射可能なインスリンおよびグルカゴン製剤ならびに投与方法 | |
JPH0386835A (ja) | 劇症肝炎治療剤 | |
UA72427C2 (en) | Water-soluble insulin preparation containing mannite, method for manufacturing composition containing soluble insulin or crystalline insulin | |
JPH07149665A (ja) | 血中アミノ酸レベルの制御方法 | |
NZ572358A (en) | Lactate and calcium containing pharmaceutical composition and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20040120 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040120 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071106 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080410 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100119 |